FDA Approves Deucravacitinib as First TYK2 Inhibitor for PsA

Published Date: 10 Mar 2026

In clinical trials, more than half of all patients treated with deucravacitinib achieved at least 20% improvement in American College of Rheumatology response criteria.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Scientists Employ Technology to Identify Plagiarism and Forgeries in Published Studies.

2.

GuCS: Genitourinary Cancers Symposium

3.

Obesity-associated cancers tripled nationwide over past two decades

4.

A new mechanism of radioresistance formation demonstrated in lung adenocarcinoma

5.

EGFR Inhibitors for Lung Cancer Tied to Increased Keratitis Risk.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot